Rivera Fernando, Vega-Villegas Ma Eugenia, Lopez-Brea Marta F, Marquez Raul
Medical Oncology Department, "Marqués de Valdecilla" University Hospital, Santander, Spain.
Acta Oncol. 2008;47(1):9-19. doi: 10.1080/02841860701704724.
EGFR overexpression usually correlates with a more advanced disease stage, a poorer prognosis and a worse chemotherapy response. EGFR expression increase has been observed in many tumours. For all the aforementioned reasons, EGFR inhibition can be considered an attractive approach in cancer treatment. One strategy has been receptor inhibition of extracellular domain using monoclonal antibodies. Cetuximab is the most developed one and there is plenty information on the literature about its current status. In this review we focus on other EGFR monoclonal antibodies under clinical development. The more developed one is Panitumumab. Its clinical development is taking place very quickly and it has mainly been studied in colorectal cancer showing promising results. There are also other interesting drugs such as Matuzumab, Nimotuzumab and Zalutumumab.
表皮生长因子受体（EGFR）过表达通常与疾病分期更晚、预后更差以及化疗反应更差相关。在许多肿瘤中都观察到EGFR表达增加。基于上述所有原因，EGFR抑制可被视为癌症治疗中一种有吸引力的方法。一种策略是使用单克隆抗体抑制细胞外结构域的受体。西妥昔单抗是研发最为成熟的一种，关于其当前状况的文献资料丰富。在本综述中，我们重点关注正在进行临床开发的其他EGFR单克隆抗体。研发较为成熟的是帕尼单抗。其临床开发进展非常迅速，主要在结直肠癌中进行了研究，显示出有前景的结果。还有其他一些有趣的药物，如美妥昔单抗、尼妥珠单抗和扎鲁单抗。
